Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18673303 | 0.90 | CNR1 (0.74) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL17694535 | 0.86 | CNR1 (0.79) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL17694537 | 0.83 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL17694536 | 0.77 | PTGFR (0.45) | CNR1CNR2 | |
| Sad448 SCHEMBL844484 | 0.75 | CNR1 (1.00) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL844571 | 0.75 | CNR1 (0.79) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL18673304 | 0.75 | PTGFR (0.44) | CNR1CNR2 | |
| SCHEMBL844174 | 0.74 | CNR1 (0.87) | CNR1CNR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL844735 | 0.73 | CNR1 (0.86) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL844333 | 0.73 | CNR1 (0.90) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9604949-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885MEN1 3189/4885 |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885MEN1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.